ACE inhibitors and angiotensin receptor blockers (ARBs) confer different cardiovascular benefits in hemodialysis (HD) patients, researchers found.
In a crossover study, 15 HD patients received placebo, the ACE inhibitor ramipril 5 mg per day for seven days, and the ARB valsartan 160 mg/day for another seven days, with a washout period of three weeks between treatments. Neither ramipril nor valsartan affected blood pressure during dialysis treatment.
Valsartan induced a greater anti-inflammatory effect compared with ramipril, but ramipril appeared to prevent dialysis-induced endothelial dysfunction, T. Alp Ikizler, MD, and colleagues reported online in the Journal of the American Society of Nephrology.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.
